8-K Announcements
6Material company update
Jun 8, 2026·SEC
Material company update
Apr 20, 2026·SEC
Material company update
Mar 30, 2026·SEC
IGC Pharma, Inc.(IGC)Earnings, Financials & Key Ratios
IGC•AMEX
$0.27
Price updated Jun 27, 2026
AboutIGC Pharma, Inc. is a clinical-stage pharmaceutical company that is focused on Alzheimer's disease, developing innovative solutions to address this devastating illness. It has two investigational drug assets targeting Alzheimer's disease: IGC-AD1, which is in a Phase 2 clinical trial as a treatment for agitation in dementia due to Alzheimer's and TGR-63 that is in pre-clinical development. In addition to its drug development pipeline, IGC Pharma seeks to leverage artificial intelligence (AI) for Alzheimer's research. The company was founded by Ram Mukunda on April 29, 2005 and is headquartered in Potomac, MD.Show more
- Revenue$1M-6.7%
- EBITDA-$10M-41.5%
- Net Income-$7M+8.0%
- EPS (Diluted)-0.07+22.3%
- Gross Margin29.68%-39.1%
- EBITDA Margin-832.97%-51.6%
- Operating Margin-860.29%-46.8%
- Net Margin-552.11%+1.5%
- ROE-105.18%-0.8%
IGC Price & Volume
IGC Pharma, Inc. (IGC) stock price & volume — 10-year historical chart
Loading chart...
Persistent Cash Burn Threatens Clinical Development Viability
Investment Thesis • Updated 2026Q4
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial Position:Vulnerable
Cash Flow:Burning
Primary Risk:Imminent liquidity and dilution
"IGC Pharma faces a precarious financial outlook characterized by a deepening $127.3 million retained earnings deficit and a lack of scalable commercial revenue to offset its $1.3 million quarterly R&D expenditure. The company's reliance on external financing is underscored by a critical liquidity shortfall, with cash balances dwindling to just $207,000 as of 2026Q4. Investors should remain cautious as the firm's inability to achieve consistent profitability or positive free cash flow necessitates potential dilutive capital raises to sustain its clinical-stage pipeline."
Verdict Logic
the company's current cash balance of $207,000 against quarterly net losses of $2.4 million indicates an imminent liquidity risk that likely necessitates further shareholder dilution.
IGC Growth Metrics
IGC Pharma, Inc. (IGC) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-15.47%
5 Years5.72%
3 Years9.19%
TTM-6.69%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM8.05%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM23.49%
Return on Capital
10 Years-57.17%
5 Years-92.56%
3 Years-117.05%
Last Year-159.4%
Peers Comparison
Key metrics vs top competitors for IGC Pharma, Inc. (IGC)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $0.27 | $26.86M | -3.71 | -6.69% | -552.11% | -105.18% | — | |
| $4.64 | $540.66M | -0.14 | 4.84% | -252.55% | -136.55% | — | |
| $1.39 | $360.29M | -32.86 | 2.82% | -1.17% | -1% | — | |
| $5.29 | $1.95B | -1.82 | 1227.6% | -19019.44% | -366.21% | — | |
| $20.69 | $2.04B | -10.04 | — | — | -102.48% | — | |
| $14.82 | $1.42B | -4.81 | — | — | -151.02% | — |
Compare IGC vs Peers
IGC Pharma, Inc. (IGC) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
IGC SEC Filings & Documents
IGC Pharma, Inc. (IGC) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when IGC posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
IGC Frequently Asked Questions
IGC Pharma, Inc. (IGC) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is IGC Pharma, Inc.'s revenue?
IGC Pharma, Inc. (IGC) reported $1.2M in revenue for fiscal year 2026. This represents a 463% increase from $0.2M in 2006.
How fast is IGC Pharma, Inc. growing?
IGC Pharma, Inc. (IGC) saw revenue decline by 6.7% over the past year.
Is IGC profitable?
IGC Pharma, Inc. (IGC) reported a net loss of $6.5M for fiscal year 2026.
Dividend & Returns
What is IGC's return on equity?
IGC Pharma, Inc. (IGC) has a return on equity (ROE) of -105.2%. Negative ROE indicates the company is unprofitable.
What is IGC Pharma, Inc.'s free cash flow?
IGC Pharma, Inc. (IGC) had negative free cash flow of $6.3M in fiscal year 2026, likely due to heavy capital investments.